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Abstract
Background: Potential adverse drug events (PADEs) are defined as being potentially harmful unintentional
medication discrepancies. Discrepancies regarding medication history (MH) often occur when a patient is being
admitted to a hospital’s emergency department (ED); they are clinically important and represent a significant source
of data regarding adverse drug events occurring during emergency admission to hospital. This study sought to
measure the impact of pharmacist-acquired MH during admission to an ED; it focused on whether a patient’s
current home medication regimen being available for a doctor when consulting a patient in an ED would have
reduced potential adverse drug events.
Method: A multicentre, double-blind, randomised, controlled parallel-group study was carried out at 3 large
teaching hospitals in Bogota, Colombia. Two hundred and seventy patients who had been admitted to an ED were
enrolled; each had a standardised, comprehensive MH interview, focusing on a patient’s current home medication
regimen prior to being seen by a doctor. Data recorded on the admission medication order form was available to
be used by a doctor during consultation in the ED. The main outcome dealt with comparing the intervention and
control groups regarding the percentage of patients having at least 1 potential adverse drug event.
Results: There were 811 PADE (3.35 per patient), 528 (65 %) on the standard care arm and 283 (35 %) on an
intervention arm. Most PADEs were judged to have had the potential to cause moderate discomfort (42.6 %),
33.4 % were deemed unlikely to have caused harm and 23.9 % were judged to have had the potential to cause
clinical deterioration.
Conclusion: Many patients suffer potentially adverse drugs events during the transition of care from home to a
hospital. Patient safety-focused medication reconciliation during admission to an ED involving a pharmacist and
drawing up a history of complete medication could contribute towards reducing the risk of PADES occurring and
improve follow-up of patients’ medication-based therapy.
Trial registration: 28/10/2012, ISRCTN63455839.
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Background
Potential adverse drug events (PADE) are defined as
being potentially harmful, unintentional medication dis-
crepancies [1]. It has been estimated that such events
account for 17 million emergency department (ED) visits
and 8.7 million hospital admissions annually in the
United States [2, 3]. They are clinically important and
represent a significant source of PADE occurring during
emergency admission to hospital. Adverse drug-related
events have recently been evaluated in ED care settings;
it has been estimated that 12 %–14.2 % of hospital ad-
missions are drug-related [4]. At least 1 medication is
omitted in more than 57 % of patients admitted to an
ED [5, 6]. Involving a pharmacist-obtained MH has been
associated with a 43 % to 84 % relative risk reduction
[7–10].
Unfortunately, the effect on PADEs on a pharmacist-
acquired medication history in an ED has not reflected
in most studies as these have been retrospective or have
analysed administrative data. Retrospective studies may
underestimate the incidence of drug-related visits be-
cause information may be missing or has been inaccur-
ately documented because patients seen in the ED for an
adverse drug-related event are typically not admitted
[11]. Studies performed to date have used different con-
cepts regarding PADE, thereby limiting comparative
evaluation and generalizability [12].
Despite the burden of drug-related morbidity and
mortality, prospective research assessing the potential
clinical importance of such discrepancies and/or the im-
pact on PADEs of an MH acquired by a pharmacist in
an ED has been limited. An attempt was made to over-
come some research limitations in this area by using a
prospective design aimed at determining whether PADE
could become reduced by a pharmacist-acquired MH in
an ED which focused on a patient’s current home medi-
cation regimen and which was available for a doctor
when consulting a patient in an ED.
Methods
Study design, setting and participants
A multicentre, double-blind, randomised, controlled
parallel-group trial study was carried out from October
26th to November 30th 2012 at 3 large teaching hospitals
in Bogota, Colombia; Fundacion Cardio Infantil, San
Carlos teaching hospital and Samaritana teaching hospital.
Each participant gave their written informed consent and
the study protocol was approved by the hospitals’ ethics
committees. A full description of the study design has
been published previously [6]. All consecutive patients
(18 years or older) who had been admitted to an ED, were
taking at least one medication or who had been prescribed
a minimum of one prescription medication before admis-
sion and who had been hospitalised for at least 24 h were
eligible for inclusion in this study. Patients were randomly
assigned to an intervention or standard care arm using
computer-generated random numbers (Microsoft Excel).
Doctors who received patients were also randomly allo-
cated; each randomisation manager made a daily alloca-
tion which depended on the number of doctors and
residents per shift. A nurse (epidemiologist) at each site
who was not involved in caring for the trial patients and
independent of the site investigator was responsible for
trial allocation and record-keeping (i.e. the randomisation
manager). (Fig. 1)
Ethics approval
The protocol and supporting documents were reviewed,
approved and registered by the following Ethics Committees
for Clinical Research: Fundacion Cardio Infantil (DDI-376,
September 18th, 2012), San Carlos teaching hospital (FHS
C-OCC 100–12, August 13th 2012), and the Samaritana
teaching hospital (142, June 27th, 2012).
Intervention
The intervention consisted of a pharmacist acquiring pa-
tients’ medication histories in an ED prior to their being
seen by a doctor. It focused on a patient’s current home
medication regimen which was documented on an ad-
mission medication order form which was available for
use by a doctor when consulting a patient in an ED. The
admitting doctors verified the data with patients and in-
dicated which home medications were to be reordered,
suspended or discontinued.
On admission to an ED
A pharmacist held a standardised, comprehensive MH
interview during ED admission, focusing on the current
home medication regimen for all the patients included
in the study, prior to being seen by a doctor. A thorough
history of all regular medication use was ascertained,
using all the following sources of information: patient
and/or caregiver interview, a check of the last prescrip-
tion and an inspection of the medicines carried by a pa-
tient (i.e. in the ED). Pharmacists conducted telephone
interviews with caregivers or family members when pa-
tients were unable to clarify their medication regimen.
This data was recorded on the admission medication
order form.
The medication order form was then used by a doctor
during consultation for issuing prescriptions in an in-
patient ED (just for the intervention group). The doctor
checked boxes to verify data with a patient and indicated
which home medications were to be reordered, sus-
pended or discontinued. This resulted in an accurate
and comprehensive history of patients’ current home
medication regimens. Relevant demographic and medical
data was collected and documented.
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Another pharmacists blinded to intervention status
reviewed each medical chart regarding all the drugs
prescribed 24 h after having been admitted to an ED.
The data came from various information sources in-
cluding a patient’s computerised hospital medical rec-
ord, the admission medication orders, the physician-
recorded MH, the nurse-recorded MH, interviews with
patients, medication administration records and demo-
graphic information. The pharmacist also attempted
to verify with patients if any medication changes had
been made since their clinical assessment (i.e. on ad-
mission to an ED). This was documented in the list of
medications prescribed by a doctor during 24 h in an
ED (F2).
Fig. 1 Study design
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Standard group
Control group patients received standard care; this in-
cluded doctors documenting medication histories in ad-
mission notes and nurses reviewing medication orders
for appropriateness. The admission medication order
form was given to the doctors at a later stage for them
to amend prescriptions made on admission. Pharmacists
would not have been routinely involved in documenting
patients’ medication histories on admission to the insti-
tutions involved in the present study; this function is
primarily the admitting resident doctor or a medical stu-
dent’s responsibility.
Medicine reconciliation process
A patient’s current home medications were compared to
medications prescribed 24 h after having been admitted
to an ED to see whether a patient’s home medications
had also been prescribed by a doctor in an ED. This was
done by an independent team consisting of a pharmacist
and a doctor blinded to intervention status. The whole
team received formal MedRec training, including a de-
scription of data-collection tools and procedures. Exter-
nal evaluation was made by the chief of each hospital’s
ED after MedRec had ended; this person then resolved
any discrepancies with each doctor. If incongruity was
detected and the reason had not been documented in
the medical record, this was clarified with the medical
team and the patients so involved. If needed, a pharma-
cist contacted a particular patient or ED doctor to clarify
any unclear medication regimen. Following MedRec,
medication continuation required that doctors write a
separate medication order.
The MedRec history (F3) (i.e. a gold standard) thus
provided an accurate and up-to-date MH for avoiding
discrepancies, such as omissions, duplications, dose er-
rors or drug interactions. This ensured that the medica-
tion list received by the next ward was correct.
Outcome
The intervention dealt with comparing the percentage of
patients in the intervention and control groups having at
least 1 PADE. A secondary outcome was recording the
number of PADEs per patient using Poisson regression
analysis.
Preparing PADE summaries
Discrepancies between a patient’s home medication and
admission ED orders were identified and intentional rea-
sons for making changes were sought from the medical
record. Clearly unintentional medication discrepancies
were recorded. The doctor blinded to intervention status
and a pharmacist involved in MedRec prepared a table
giving a detailed description of medication discrepancies,
including prescribed medication, drug class and type of
discrepancy which could have been associated with any
of the following: drug, dosage, frequency, administration
route, appropriateness of restarting medication, thera-
peutic duplicity and/or medications lacking indication
for use. The list was independently sent to two reviewers
who judged each medication discrepancy for its potential
to cause harm.
Determining the potential to cause harm
Such medication discrepancies’ clinical severity was in-
dependently assessed by two clinical pharmacists blinded
to the patient data collection forms. Classifying the de-
gree of effect was adapted from the method used by
Cornish et al. [13]. A Class 1 discrepancy was unlikely
to result in clinical deterioration. An example would be
a patient being prescribed 10 mg/d of desloratadine on
admission, despite a 5 mg/d dosage having been re-
ported during the interview. Class 2 discrepancies were
those having the potential to cause moderate clinical de-
terioration. An example would be a patient for whom
10/d mg atorvastatin and 20 mg/d omeprazole had
been omitted from the drugs prescribed on admission,
despite such patient having reported that these were
frequently taken at home during the interview. Class 3
discrepancies would have resulted in a patient’s severe
clinical deterioration. An example would be when a
cardiac arrhythmia patient had been admitted to hos-
pital and been prescribed 150 mg/d propafenone despite
having reported that he had been taking propafenone dur-
ing the interview; however, the ED doctor did not know
that a lower dose (half of that prescribed) had already been
ordered by a cardiologist 3 weeks earlier. If agreement was
not found, an internist independently rated the event and
consensus was reached regarding all discrepancies.
Statistical methods
Fleiss’ kappa coefficient was used for assessing the level
of agreement among evaluators when judging PADEs.
Patients’ characteristics were calculated using percent-
ages, means, standard deviations and inter-quartile
ranges. The number of PADEs per patient was identified
by an exact X2 test to investigate differences between
treatment groups regarding the percentage of patients
having at least 1 PADE. Univariate and multivariate lo-
gistic regression analysis was used to investigate predic-
tors of at least 1 PADE and analyse the risk ratio
between the intervention and control groups. Poisson
regression analysis was used to determine associations
between the number of PADEs per patient and study
group characteristics. All tests were 2-tailed and a p < 0.05
test result was deemed statistically significant. All statis-
tical analysis involved using R statistics software.
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Results
Participant flow
The 270 randomised patients selected by consecutive
sampling for the study (134 intervention and 136
controls) were cared for by each of the 3 randomised
teams and by 91 admitting doctors. Twenty-eight pa-
tients (17 interventions and 11 controls) were ex-
cluded; the usual reason for exclusion was they had
been assessed and ranked incorrectly during triage,
were discharged on the same day or voluntarily de-
cided to leave the hospital and seek care at another
hospital. (Figures 2 and 3).
Patient demographics and clinical characteristics
There were no statistically significant differences be-
tween both treatment arms; patients’ had similar
Fig. 2 Flow diagram regarding participants
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Fig. 3 CONSORT checklist of information.
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characteristics regarding the intervention and standard
care arms. The characteristics of patients in the study
population are summarised in Table 1.
The effect of the intervention on PADEs
There was very good reliability concerning judging dis-
crepancies’ potential severity. Fleiss’ kappa coefficient
was used (κ = 0.829: 0.7-0.96 95 % CI) and consensus
was easily achieved in areas of disagreement [14].
The relative risk of at least 1 PADE having occurred
per patient was evaluated for each class of PADE; 37
(31 %) of the intervention group had suffered class 3
PADE compared to 70 (56 %) in the control group
(0.56 RR: 0.41-0.77 95 % CI). Reduced adjusted rela-
tive risk due to the effect of the intervention was
56 %. Regarding class 2 PADEs, 44 (38 %) were iden-
tified in the intervention group compared to 93
(74 %) in the control group (0.51 RR: 0.39-0.65 95 % CI);
reduced adjusted relative risk due to the effect of the inter-
vention was 50 %. Fifty-three (45 %) class 1 PADEs were
detected in the intervention group compared to 80 (64 %)
in the control, giving 70 % reduced adjusted relative risk
(0.71 RR: 0.56-0.90 95 % CI).
PADE type and potential severity
The study revealed 811 PADEs (an average of 3.35 per
patient; 528 (65 %) occurred on the standard care arm
and 283 (35 %) on the intervention arm. Most PADEs
were judged to have been capable of causing moderate
deterioration (42.6 %), 33.4 % of the PADEs were
deemed unlikely to have caused harm and 23.9 % were
judged to have been able to cause clinical deterioration.
The omission of medication was the most frequently oc-
curring type of PADE able to cause patients’ significant
clinical deterioration.
Table 2 shows the types of PADE according to their se-
verity and distribution in intervention and control groups.
There was an increase in those related to administration
regimen (slow to restart drug therapy or too soon to re-
start drug therapy) following the intervention and not a
reduction, as expected. Slowness to restart drug therapy
increased by 6.64 % in class 1, 37.5 % in class 2 and 17.4 %
in class 3; an increase in the number of too soon to restart
drug therapy type cases was also observed in the interven-
tion group: 0.26 % in class 1, 0.85 % in class 2 and 2.82 %
in class 3. Slowness and/or being too early in restarting
therapy involving drugs was related to a mismatch be-
tween the scheduled administration times at a particular
hospital and the patients’ usual administration times. The
number of cases involving the intervention group was al-
most always lower than in the control group regarding the
other types of PADE.
The association between PADEs and baseline patient
characteristics was also evaluated (Table 3). Increased
age, being female, the number of comorbidities, the
number of hospitalisations and number of drugs being
taken were predictors of increased univariate model
probability of at least 1 PADE occurring. Regarding the
study population’s clinical characteristics in the multi-
variate model, intervention and ED setting were signifi-
cant variables regarding a reduced risk of at least 1
PADE occurring per patient. The number of drugs taken
at home increased the risk of PADEs occurring.
Poisson log-linear regression led to obtaining
measurements of relative risk associated with each
covariate; Table 4 gives the measurements regarding
increased or reduced relative risk associated with each
co-variable. All variables in the univariate model were
seen to be significant (particularly ED setting and
intervention) in reducing the risk of a PADE occurring.
Table 1 The study population’s baseline demographic and clinical characteristics
Characteristics Total group Control Intervention Value p value
242 (100) 125 (51.65) 117 (48.35)
Age, mean ± SD 59 ± 19 58 ± 20 59 ± 18 −0.5355a 0.5928
Gender 0.2233b 0.6365
Female 140 (57.9) 70 (56.0) 70 (59.8)
Male 102 (42.1) 55 (44.0) 47 (40.2)
No. of hospitalisations, mean (IQR, min, max) 0 (1, 0, 12) 0 (1, 0, 10) 0 (1, 0, 12) −0.2168a 0.8285
No. of co-morbidities, mean (IQR, min, max) 1 (2, 0, 4) 1 (2, 0, 4) 1 (1, 0, 4) 0.4219a 0.6735
No. of medicines, mean (IQR, min, max) 4 (4, 1, 12) 4 (4, 1, 16) 4 (4, 1, 14) −0.3299a 0.7418
Teaching hospitals 5.1145b 0.07752
Fundacion Cardioinfantil 82 (33.9) 36 (28.8) 46 (39.3)
San Carlos hospital 78 (32.2) 48 (38.4) 30 (25.6)
Samaritana hospital 82 (33.9) 41 (32.8) 41 (35.1)
aStudent’s t-test; bChi-square; SD (standard deviation). IQR, interquartile range; min, minimum; max, maximum
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Age, the number of comorbidities and ED setting asso-
ciated with the San Carlos hospital were not significant
in the multivariate model regarding the possibility of
risk occurring.
Discussion
The intervention was associated with a significant
reduction in the severity of any type of PADE con-
cerning admission to an ED, shown by the relative
risk of at least 1 PADE occurring in each class. Our
results were consistent with previous studies [8, 15].
Schnipper et al., [7] found that the effectiveness of
having a pharmacist involved in healthcare acquiring
patients’ medication histories led to reducing the oc-
currence of at least 1 PADE per patient; such result
was very similar to that found in this study. Regard-
ing PADE potential severity, there were fewer medi-
cation omissions in the intervention, probably due to
doctors having more information available when pre-
scribing medication during ED consultation and as
such information could have been verified together
with patients.
The study also detected an unexpected rise in the
amount of PADEs related to restarting therapy
(promptness or slowness) in the intervention group.
Percentage variation regarding slowness was greater
for both groups and all types of PADE severity.
Greater promptness in administering medicine could
have been associated with doctors giving priority to
critical events in an ED and patients’ home adminis-
tration regimens being omitted. Such was the re-
searchers’ perception as it was not a previously
established result and requires further investigation.
The potential risks of unsuitable management re-
garding administration frequency could have been
associated with the probable appearance of thera-
peutic failure due to drug concentration in blood
not reaching the therapeutic minimum, e.g. when
delay in administering medication was more than
24 h or, contrarily, administering medicines with
greater frequency than that established in posology
Table 3 Association between patients’ baseline characteristics and at least 1 PADE
Characteristics Univariate logistic regression Multivariate logistic regression
Odds ratio (95 % CI) p-value Odds ratio (95 % CI) p-value
Age 1.02 (1.01 - 1.04) 0.0043 1.01 (0.99 - 1.03) 0.2770
Being female 1.76 (1.05 - 2.98) 0.0344 1.56 (0.83 - 2.93) 0.1673
Teaching hospital ED
San Carlos 0.52 (0.28 - 0.97) 0.0417 0.47 (0.21 - 1.01) 0.0542
La Samaritana 0.28 (0.14 - 0.53) 0.0001 0.22 (0.09 - 0.48) 0.0002
Number of hospitalisations 1.27 (1.03 - 1.63) 0.0369 1.29 (1.00 - 1.74) 0.0713
Number of comorbidities 1.35 (1.07 - 1.73) 0.0137 0.71 (0.49 - 1.00) 0.0511
Number of home medications 1.34 (1.21 - 1.50) 7.75E-08 1.36 (1.19 - 1.58) 1.75E-05
Intervention 0.36 (0.21 - 0.61) 0.0002 0.22 (0.11 - 0.42) 5.64E-06
CI confidence interval, ED emergency department
Table 2 Discrepancy type and potential severity
Type of PADE Class 1a Class 2b Class 3c
Total group Control Intervention Total group Control Intervention Total group Control Intervention
Incorrect or omitted dose 39 (14.4) 22 (13.2) 17 (16.4) 32 (9.3) 12 (5.0) 20 (18.5) 94 (48.5) 49 (39.8) 45 (63.4)
Therapeutic duplication 4 (1.5) 3 (1.8) 1 (1.0) 0 (0) 0 (0) 0 (0) 1 (0.5) 1 (0.8) 0 (0)
Incorrect or omitted frequency 0 (0) 0 (0) 0 (0) 4 (1.2) 4 (1.7) 0 (0) 2 (1.0) 2 (1.6) 0 (0)
Slow to restart drug therapy 28 (10.3) 13 (7.8) 15 (14.4) 103 (29.8) 43 (18.0) 60 (55.6) 25 (12.9) 8 (6.5) 17 (23.9)
No indication 0 (0) 0 (0) 0 (0) 2 (0.6) 2 (0.8) 0 (0) 0 (0) 0 (0) 0 (0)
Drug omission 190 (70.1) 123 (73.7) 67 (64.4) 187 (54.0) 164 (68.9) 23 (21.3) 70 (36.1) 63 (51.2) 7 (9.9)
Too soon to restart drug therapy 10 (3.7) 6 (3.6) 4 (3.9) 14 (4.1) 9 (3.8) 5 (4.6) 2 (1.0) 0 (0) 2 (2.8)
Inappropriate or omitted route 0 (0) 0 (0) 0 (0) 4 (1.2) 4 (1.7) 0 (0) 0 (0) 0 (0) 0 (0)
aClass 1: discrepancies unlikely to cause patient discomfort or clinical deterioration. bClass 2 discrepancies which could cause moderate discomfort or
clinical deterioration
cClass 3 discrepancies potentially resulting in severe discomfort or clinical deterioration
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could have eventually provoked an unexpected in-
crease in drug concentration in blood, thereby in-
creasing the risk of a PADE occurring. All of the
foregoing should be evaluated by a doctor and would
depend on the type of medicament being taken and
a patient’s clinical condition.
An increase in PADEs may be explained by many
events (according to the researchers’ un-programmed
observations), but may have been caused because the
hospitals had previously established nursing services’
medicament administration times/schedules as their
current hospital policy. A pharmacist-acquired MH in
an ED may have guaranteed that doctors had more in-
formation available regarding patient medication during
consultation, thereby reducing prescription errors and
contributing towards more widespread introduction of
new medication regimes [16].
Analysing the explanatory models’ results revealed
that the PADEs reported in this study agreed with
findings from other studies. Gender was associated as a
characteristic predicting an increased risk of a PADE
happening in the present study (Tables 3 and 4). Other
studies have concluded that differences regarding
pharmacokinetics, pharmacodynamics and medication
side-effects were gender-dependent and may have
reflected response profiles concerning drugs’ different
effects. The effect of gender on drug response repre-
sents a very recent field of research for most drugs; the
effect of specific dosage and administration route have
begun to be explored even more recently, thereby indi-
cating the need for specific gender analysis as the only
suitable procedure for detecting such differences (Mei
et al., [17], Anderson et al., [18]).
The high number of co morbidities has increased the
number of hospitalisations due to the association be-
tween variables and the number of medicines being
taken. The multivariate model showed that only the
number of medicaments and an increased risk of class 3
PADE occurring were statistically significant. The inter-
vention was associated with a significant reduction in
PADEs at the Samaritana hospital but not at the other
hospitals involved in the study (Table 4).
It was thus noted that some differences concerned
particular hospitals in the study, particularly the Samari-
tana hospital, probably due to specific features concern-
ing the service offered during ED admission and maybe
due to the patient:doctor ratio being the lowest of the
three hospitals and more time being spent on average
during consultation. The aforementioned points are
speculative since the patient:doctor ratio and consult-
ation duration were not variables which were measured
at the start of the study and thus do not represent a con-
clusion resulting from an analysis of the information
made available during the study. Although the hospitals
participating in the study were selected as they had very
similar general characteristics, it was revealed that an
ED healthcare setting significantly affected the risk of
PADEs occurring.
Both models led to concluding that the intervention
reduced adverse events occurring due to patients’ medi-
cation errors and that percentage reduction was statisti-
cally significant, probably due to the intervention group
having a more complete MH available and MedRec mak-
ing this safer.
The models were consistent regarding the clinical var-
iables supporting their explanation whilst differences
between estimated models showed that sociodemo-
graphic variables (age and gender) were significant in
the Poisson model. This could have been due to a strong
association of such factors with the number of PADEs
and not with the presence of at least 1 PADE. Identify-
ing a single risk can be considered as one of four im-
portant steps regarding the safe use of medicines: risk
detection, risk assessment, risk minimisation and risk
Table 4 Association between patients’ baseline characteristics and the number of class 3 PADEs
Characteristics Univariate poisson regression Multivariate poisson regression
Estimate (95 % CI) p - value Estimate (95 % CI) p - value
Age 1.02 (1.01; 1.03) 2.58E-05 1 (0.99; 1.01) 0.4377
Being female 2.03 (1.82; 2.83) 1.19E-05 1.49 (1.06; 2.12) 0.0235
Teaching hospital ED
San Carlos 0.73 (0.52; 0.99) 0.0462 0.99 (0.7; 1.4) 0.9731
La Samaritana 0.4 (0.27; 0.58) 2.12E-06 0.46 (0.3; 0.69) 0.0003
Number of comorbidities 1.32 (1.17; 1.49) 3.05E-06 0.91 (0.78; 1.06) 0.2275
Number of hospitalisations 1.16 (1.08; 1.22) 4.66E-06 1.13 (1.04; 1.22) 0.0019
Number of home medications 1.23 (1.19; 1.3) <2e-16 1.19 (1.13; 1.26) 1.18E-09
Intervention 0.62 (0.46; 0.83) 0.0012 0.6 (0.44; 0.8) 0.0007
CI confidence interval, ED Emergency Department
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communication. However, a typical individual medicinal
product will have multiple risks attached to it and indi-
vidual risks will vary in terms of severity, a particular
patient and public health impact. The combination of
information regarding potential adverse drugs events
could thus ensure that the benefits exceed the risks by
the greatest possible margin both for individual patients
and the population as a whole.
This study had several limitations. Despite the study
having been conducted in teaching hospitals, it may not
be possible to extrapolate the results to other settings
because an ED setting was a factor regarding the risk of
a PADE occurring. Future research could examine the
effect of an ED admission setting and blocking; a cluster
study should thus be carried out.
Error rates may differ regarding services other than an
ED concerning admissions which are elective or involve
a transfer from another healthcare facility, or concern
patients taking more than 1 medication. Our findings
may not have been representative of other institutions
which do not use MedRec on admission. Eligible pa-
tients were not followed-up beyond the study; the effect
of such ED admission process on medical outcome is
thus unknown.
The rating method used for assessing the potential se-
verity of discrepancies and the admission medication
order form (F1) questionnaire used during a MH inter-
view have not been validated. Intra-researcher agreement
was not evaluated as interviewing the same patient twice
could have led to recall bias.
The hospitals involved in this study are currently de-
veloping a MedRec pathway which will incorporate some
strategies based on the findings from the present study.
The next phase of this study will involve an assessment
of medication discrepancies once the new MedRec
protocol is in place.
The potential risk of adverse events was evaluated by
groups of drugs (e.g. cardiovascular or gastrointestinal
drugs) and not by specific medicaments (e.g. digoxin or
warfarin). This was due to the large amount of drugs be-
ing taken by the patients in the study. Some risks produ-
cing moderate clinical deterioration may not have been
considered, because only those threatening a patient’s
life were taken into account (i.e. class 3), thereby limit-
ing the analysis.
Conclusions
It was concluded that potentially adverse drug events
occur for many patients during the transition of care
from home to hospital. Patient safety-focused MedRec
during admission to an ED involving a pharmacist and
drawing up a complete MH could thus contribute to-
wards reducing the risk of PADEs occurring and could
improve patients’ medicament-based follow-up therapy.
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